ClinicalTrials.gg
Not yet recruitingNCT06422624Updated May 22, 2024

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

A Phase 1 interventional study of Semaglutide Extended-release for Injectable Suspension, 1 mg and Semaglutide Extended-release for Injectable Suspension, 4 mg in Diabetes Mellitus, Type 2, sponsored by Bostal Drug Delivery Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Bostal Drug Delivery Co., Ltd · Phase 1, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.

02

Conditions studied

  • Diabetes Mellitus, Type 2
03

In context

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 14 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Bostal Drug Delivery Co., Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. He/She should provide written .
  2. He/She must be a healthy adult human male or non-pregnant, non-lactating females,18 - 45 years of age (both years inclusive).
  3. He/She should have a ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 with body weight at least 55 kg for men and at least 48 kg for women.
  4. He/She should have a baseline systolic blood pressure with upper limit of less than 140 mmHg and lower limit of more than or equal to 100 mm Hg. Similarly baseline diastolic blood pressure with upper limit less than 90 mm Hg and lower limit more than or equal to 60 mmHg.
  5. He/She should have pulse rate not less than 60 beats/min and not more than 100 beats/min and respiratory rate not less than 14 breaths/min and not more than 18 breaths/min.
  6. He/She must be of normal health as determined by medical history (including medication history) and physical examination performed within 21 days prior to the dosing.
  7. He/She should have normal , chest X-ray and vital signs.
  8. He/She should have normal or clinically non-significant thyroid function tests (T3, T4 and TSH).
  9. Availability of a study volunteer for the entire study duration and willingness to adhere to protocol requirements as evidenced by written informed consent.
  10. If study volunteer is a female and is of child bearing potential practicing an acceptable method of such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence for the duration of the study as judged by the investigator(s), or If she is with spontaneous amenorrhea for at least 01 year. or If she is surgically sterile (had a bilateral tubal ligation, bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 06 months).

Exclusion criteria

Exclusion Criteria:

  1. He/She is incapable of understanding the .
  2. He/She has a history of (e.g. anaphylactic reactions, angioedema and serious skin reactions) or idiosyncratic reaction to active or inactive ingredient in the Semaglutide extended-release injectable suspension or any other related drugs.
  3. He/She has a history of impairment of renal, hepatic, cardiac, pulmonary or gastrointestinal function.
  4. He/She has a history of tuberculosis, epilepsy, asthma, diabetes, psychosis and eye disorders.
  5. He/She has history of any pulmonary disorder (, Asthma, Bronchitis, other respiratory disorders) and skin related disorders.
  6. He/She has a personal or family history of Medullary Thyroid Carcinoma (MTC) or any other thyroid tumors or Multiple Endocrine Neoplasia 2 (MEN 2) or any other endocrine disorders.
  7. He/She has a history of pancreatitis, diabetic retinopathy, gall bladder disease.
  8. He/She has undergone surgery within the past 3 months prior to screening, or those planning to undergo surgery during the trial period.
  9. He/She has any difficulty in swallowing.
  10. He/She regularly smokes more than 10 cigarettes daily or has difficulty in abstaining from tobacco for the entire study duration.
  11. He/She has taken over the counter or prescribed medications, including vitamins, herbal supplements, insulin or drugs which promote insulin secretion, Sulfonylureas, any oral medications or any systemic medication within the past 30 days prior to dosing.
  12. He/She has a history of any psychiatric illness, which may impair the ability to provide written, informed consent.
  13. He/She has a history of alcohol or substance abuse within the last 05 years.
  14. He/she using prohibited medications (e.g., sedative hypnotics, CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating antiepileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants).
  15. He/She has abnormal values of laboratory parameters.
  16. He/She has participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 90 days.
  17. He/She is unable to or unlikely to be compliant with protocol requirements or restrictions.
  18. He/She, in whom study drug is for medical reasons.
  19. He/She is intolerant to venipuncture.
  20. Positive results at screening for , surface antigen (HBsAg), Virus (HCV) or syphilis.
  21. Female volunteer who has used implanted or injected hormonal anytime during the 06 months prior to study or used oral contraceptives within 14 days before dosing.
  22. Female volunteer who demonstrates a positive pregnancy test.
  23. Female study volunteer who is pregnant, breast-feeding or who is likely to become pregnant during the study.
  24. Female using Hormonal IUD (Mirena), Norplant and other hormones, Depo-Provera, OCPs. (Females of child bearing age will be required to use 2 reliable forms of contraception such as condom and spermicidal or barrier method and spermicidal if sexually active. However, the use of Copper IUD or Tubal ligation are sufficient).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Semaglutide ER Injectable Suspension, 1 mg

    Participants receive a single of semaglutide ER injectable suspension at a lower dose 1 mg for safety, tolerability and pharmacokinetics assessements

    Drug: Semaglutide Extended-release for Injectable Suspension, 1 mg

  • Experimental
    Semaglutide ER Injectable Suspension, 4 mg

    Participants receive a single of semaglutide ER injectable suspension at a medium dose 4 mg for safety, tolerability and pharmacokinetics assessements

    Drug: Semaglutide Extended-release for Injectable Suspension, 4 mg

  • Experimental
    Semaglutide ER Injectable Suspension, 8 mg

    Participants receive a single of semaglutide ER injectable suspension at a higher dose 8 mg for safety, tolerability and pharmacokinetics assessements

    Drug: Semaglutide Extended-release for Injectable Suspension, 8 mg

Interventions

  • DrugSemaglutide Extended-release for Injectable Suspension, 1 mg

    Singel-dose; Subcutaneous

  • DrugSemaglutide Extended-release for Injectable Suspension, 4 mg

    Singel-dose; Subcutaneous

  • DrugSemaglutide Extended-release for Injectable Suspension, 8 mg

    Singel-dose; Subcutaneous

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: From time zero up to the last time point with measurable concentration

  2. AUC0-t

    Area under the plasma concentration time curve from time zero to the last measurable concentration

    Time frame: From time zero up to the last time point with measurable concentration

  3. AUC0-inf

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: From time zero up to the last time point with measurable concentration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Nov 2024, 3 months later.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 3 months is below that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartEst.
Aug 2024
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06422624
Lead sponsor
Bostal Drug Delivery Co., Ltd
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Aug 2024 (estimated)
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
May 22, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion